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Comparison of pituitary-thyroid function in patients with end-stage
renal disease and in age- and sex-matched controls. The response to iv.
bolus thyrotropin-releasing hormone (TRH) of 14 dialysis patients with
end-stage renal disease (ESRD) was compared to the response of 14
age- and sex-matched renal clinic patients (controls) with normal renal
function (serum creatinine concentrations < 1.2 mgldl). The mean basal
serum levels of thyrotropin (TSH) were similar in the two groups. There
was no difference between the two groups in the mean maximal increase
in TSH after TRH (6.3 ii.U/ml and 7.2 U/ml in ESRD and control
groups, respectively); The rate of fall in TSH from 60 to 90 mm after
TRH was slower in the ESRD group than in the controls. The mean
increase in serum triiodothyronine (T3) concentration after TRH was
similar in both groups (25.4 ng/dl, ESRD; 18.4 ng/dI, controls). As
previously reported, basal serum T1 content was subnormal in the
ESRD patients. Serum thyroxine (T4) concentrations were comparable
in control and ESRD groups and did not change significantly during the
90-mm TRH test in either group. We conclude that ESRD patients,
clinically stable on dialysis, have normal pituitary TRH responsiveness
and normal thyroidal response to endogenous TSH secretion, as
compared with an age- and sex-matched group of patients with normal
renal function. The results of this study support the contention that
ESRD patients are eumetabolic.
Comparaison de Ia fonction hypophyso-thyroidienne chez les malades
en insuffisance rénale terminale et chez des contrôles de méme age et sexe.
La réponse a l'injection d'un embol de TRH a 14 malades en dialyse
atteints d'insuffisance rénale terminale (ESRD) a été comparée a Ia
response obtenue chez 14 malades de mêmes age et sexe dont Ia
fonction rénale était normale (concentration sérique de créatinine < 1,2
mg/dl). La concentration sérique moyenne basale de TSH était sembla-
ble dans les deux groupes. 11 n'y avait pas de difference entre les deux
groupes pour Ia moyenne d'augmentation maximale de TSH aprês TRH
(6,3 p.U/ml et 7,2 p.UIml dans les groupes ESRD et contrôle respective-
ment); Ia chute de TSH de 60 a 90 mm apres TRH était plus lente dans le
groupe ESRD que dans les contrOles. L'augmentation moyenne de la
concentration sérique de T1 après TRH était semblable dans les deux
groupes (25,4 ng/dl, ESRD; 18,4 ng/dl, contrOles). Comme il a été
rapporte antérieurement, Ia concentration sérique de T3 basale était
inférieure a Ia normale chez les malades ESRD. La concentration
sérique de thyrosine (T4) était comparat le dans les groupes contrôle et
ESRD et n'a été significativement mod flee pendant les 90 mm apres
TRH dans aucun groupe. Nous concluons que les malades ESRD,
cliniquement stables ou en dialyse, ont une capacité de réponse
hypophysaire a TRH normale et une réponse thyroldienne normale a Ia
sécrétion endogene de TSH par comparison avec des sujets de mémes
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age et sexe dont Ia fonction rénale est normale. Les résultats de cette
étude sont en faveur de Ia théorie selon laquelle les malades ESRD sont
eu-metaboliques.
A variety of pituitary-thyroid function test abnormalities
have been reported in patients with end-stage renal disease
(ESRD). These include depressed serum triiodothyronine (T3)
concentrations [1—61, low normal [1, 2, 4] or low [3, 5, 6] serum
thyroxine (T4) levels and subnormal serum T4 and T3 increases
after administration of exogenous thyrotropin (TSH) [5]. In
spite of these findings, basal serum TSH levels have usually
been normal [1—6]. The pituitary TSH response to i.v. thyrotro-
pin-releasing hormone (TRH), however, has been variably
described as exaggerated, normal [7, 8], or depressed [1, 3, 4,
8], with a delayed return of serum TSH to basal levels [1, 4].
When control subjects have been included in these several
studies, they have often not been age- or sex-matched with
ESRD patients [1, 5].
We have concluded elsewhere [2] that patients with ESRD
and low serum T3 concentrations are eumetabolic, based on
determinations of the basal metabolic rate, the Q-Kd interval,
and the Achilles tendon reflex half-relaxation time. These
studies did not preclude the possibility that subtle abnormalities
of TRH responsiveness existed in our ESRD patients. In the
current study we have tested the responsiveness of the pitu-
itary-thyroid axis to TRH administration in a group of ESRD
patients who were clinically stable on chronic dialysis. We have
compared these results to those obtained in a control group of
age- and sex-matched patients with normal renal function.
Methods
Fourteen patients with ESRD who were clinically stable on
outpatient dialysis programs at the Erie County Medical Center
and Baltimore City Hospitals were serially admitted to the
study. Twelve were on a hemodialysis program and two on
intermittent peritoneal dialysis. There were 8 males and 6
females; the mean age was 38.5 years (range 27 to 63 years) and
the mean pre-dialysis serum creatinine concentration was 18.6
mgldl. Fourteen age- and sex-matched control patients from the
renal-hypertension clinics of both institutions were identified;
this group had a mean age of 38.2 years (range 22 to 63 years)
and a mean serum creatinine of 0.9 mg/dl (range 0.6 to 1.2
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Table 1. Basal serum thyroid function tests
Hormone concentration
ESRD
mean SEM
Co
mean
ntrol
SEM P
TSH, U/ml 5.5 0.7 4.5 0.7 NS
T3, ng/dl 69.9 4.1 99.1 5.7 <0.001
T4, i.g/dl 5.2 0.6 6.3 0.7 NS
o P was calculated by the unpaired r test.
Abbreviations used are defined: ESRD, end-stage renal disease; TSH, thyrotropin; T3, serum triiodothyronine; T4, serum thyroxine.
—
variation for T4 were both 6%, and for T3 were 5 and 6%
respectively. The normal range of T4 in our laboratory is 5.0 —
13.0 pgIdl, defined as the limits which enclose 95% of all T4
determinations made on normal sera. The mean normal serum
T4 concentration in our laboratory is 7.50 p.g/dl. The normal
range for serum T3 is 73 — 196 ng/dl (mean, 139 ng/dl),
determined in the same way. Serum TSH concentrations were
measured by radioimmunoassay [10]; our normal range for
basal TSH is 6.5 UIml, while the normal increment in TSH
after TRH is 3 to 20 p.U/ml.
The results are presented as the mean SEM, and compari-
sons of samples taken at different time points during TRITI tests
were performed by the paired t test. Comparisons of the ESRD
samples with those of the controls were made by the unpaired
test.
Results
Serum TSH concentration, response to TRH. Themean basal
serum TSH concentration was normal in both ESRD and
• control groups (see Table 1 and Fig. I, top panel). Following
TRH administration the mean TSH level increased by a maxi-
mum of 6.3 2.6 .tU/ml in the ESRD group, reaching a peak
response at 45 mm; the mean TSH level increased by a
maximum of 7.2 1.2 U/ml in the control group, reaching a
peak response at 30 mm after TRH. At no point in time was
there a significant difference in mean TSH concentration be-
tween the two groups.
The fall in serum TSH after achieving the peak level was
minimal up to 90 mm in the ESRD subjects. The mean ratio of
60- to 90-mm TSH levels in the ESRD group was 1.1, while it
was 1.3 in the controls; this difference in ratios was significant
(P < 0.02 by unpaired t test).
Basal serum T3 concentration and the response of serum T
to TRH. ESRD patients showed significantly depressed basal
serum T3 concentrations as compared to the control levels
(Table 1 and Fig. 1, lower panel). A response of serum T3 to
TRH administration was seen in both groups, with an overall
increase in the mean T3 concentration of 25.4 6.2 ng/dl in the
ESRD patients, and 18.4 3.7 ng/dl in the controls. There was
no significant difference between these two increments. The 90-
mm T3 levels were significantly higher than 0 time values in
both groups (P < 0.01).
Basal serum T4 concentration and the response of serum T4
to TRH. The mean basal serum T4 concentrations were not
statistically different in our two study groups (Table 1). There
were no significant changes in serum T4 concentration during
the course of the TRH test in either group (data not shown).
Serum T4 and T3 concentrations were not significantly differ-
ent in the ESRD subjects receiving anabolic steroid therapy, as
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Fig. 1. Change in serum TSH (upper panel) and T-, (lower panel)
concentrations after TRH 500 p.g iv. in 14 ESRD patients on dialysis
and 14 age- and sex-matched control subjects. Shown are the mean
hormone levels SEM.
mg/dl). These patients were asymptomatic and clinically stable;
they had experienced no weight loss in the 6 months prior to
study. No patients in either the ESRD or control groups were
taking medications known to affect thyroid function tests,
except for 4 ESRD patients who were given nandrolone phen-
proprionate, an anabolic steroid. All patients gave informed
consent to the study, which was approved by the Human
Research Committees of both institutions.
The subjects were studied in the fasting state in the morning;
ESRD patients were tested on the day of dialysis, prior to that
procedure. ESRD patients and controls received TRH (Thypi-
none, Abbott), 500 p.g i.v. over I mm, with venous blood
obtained at 0 time and 15, 30, 45, 60, 75 and 90 mm after the
TRH injection, for determination of T4, T3, and TSH concentra-
tions. Radioimmunoassays for T4 and T3 were carried out by
the method of Mitsuma et al [9], with a bound-free separation
effected by charcoal. Intra- and inter-assay coefficients of
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compared with other ESRD patients. Similarly, nandrolone
effected no differences in basal TSH levels or the increase in
TSH after TRH.
Discussion
The administration of TRH to ESRD patients on long-term
dialysis and to a group of control renal clinic patients with
normal renal function has shown no difference between these
groups in terms of responsiveness of the pituitary-thyroid axis.
A number of reports have contended that abnormalities of
pituitary-thyroid function are common in ESRD [1—8]. In a
previous study, however, we concluded that ESRD patients
who are stable on dialysis are eumetabolic, despite decreased
serum T5 content and borderline low serum T4 levels [2]. We
believe that these changes are not distinctive for ESRD but
reflect the "euthyroid sick" state [11] in which euthyroidism
may be maintained either by normal serum levels of free T4 [2]
or by conservation of normal amounts of intracellular T3 [12—
14]. In the present study, we have concluded that there is no
TRH-response abnormality typical for ESRD and that when
TRH-testing in ESRD patients is compared with a population of
appropriate controls, there is no difference in results between
these groups. In addition, the response of the thyroid gland in
our ESRD patients to endogenous TSH appears normal in terms
of thyroid hormone release.
The lack of concordance in results of studies of thyroid
function in uremia is not surprising when the following factors
are considered: (1) Submaximal doses of TRH have been used
in some studies [8]; (2) study populations have been heteroge-
neous in terms of degree of renal failure and stability of clinical
state ( 'sickness"); and (3) when control subject data have been
reported [1, 5], they have been derived without regard for the
known effects of increasing age and maleness on TRH-respon-
siveness [15—171. These factors are likely to contribute to the
impression of depressed TRH-responsiveness in ESRD. In the
present study design, we employed a TRH dose which is
maximal in effect [15] and included dialysis patients with stable
cardiovascular status and body weight. We also identified a
group of healthy age- and sex-matched outpatient controls to
limit the effects of these variables on conclusions we may draw
from the results of TRH-testing.
The findings of Gonzalez-Bar cena et al [18] in eight patients
are similar to our own, showing a normal post-TRH rise of
serum TSH, with a delayed fall in TSH thereafter. The latter
effect has been reported by others [1, 4] and may be due to
delayed renal clearance of TSH.
The absolute rise in serum T3 content after TRH was signifi-
cant and of comparable magnitude in ESRD and control groups,
consistent with the response reported in normal subjects [19]
and in some ESRD patients of Weissel et al [8]. Thus, we find
no evidence to support the conclusion [1, 4] that an abnormal
thyroidal secretory response to endogenous TSH exists in
ESRD. The lack of rise in serum T4 after TRH administration is
normal for a TRH study of a 90-mm duration.
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